Inhaled tobramycin versus intravenous tobramycin for patients with cystic fibrosis: a review of the clinical effectiveness, cost effectiveness, and guidelines
CADTH
Record ID 32014000212
English
Authors' recommendations:
No evidence was identified comparing the clinical and cost effectiveness of inhaled tobramycin to IV tobramycin in the treatment of CF patients. A nephrotoxicity study of tobramycin on CF patients found that long-term use of neither inhaled nor IV tobramycin was associated with a decline in kidney function. Adherence rates with inhaled tobramycin were low. Despite no association found between inhaled tobramycin adherence and the frequency of pulmonary exacerbation, compared to patients with high adherence with inhaled tobramycin, those using less than 4 cycles of TIS per year were more likely to be hospitalized. Guidelines from the CF Foundation recommended that alternate month tobramycin solution for inhalation should be used chronically for infants who remain infected with PA after two attempts at eradication.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/jul-2013/RC0429%20Inhaled%20versus%20IV%20tobramycin%20for%20CF%20final%20v2.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Administration, Inhalation
- Tobramycin
- Injections, Intravenous
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.